

# Targeting New Treatments in Cervical Cancer

A GOG Foundation, Inc. Independent Satellite Symposia

Thursday, September 9, 2021

# GOG FACULTY DISCLOSURE INFORMATION

Virtual Symposium, “Targeting New Treatments in Cervical Cancer”

**SEPTEMBER 9, 2021**

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** \*(formally known as commercial interests). All **Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations.**

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within **the past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

**All of the relevant financial relationships listed for these individuals have been mitigated.** However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

**NEW TERM** \*An “**ineligible company**” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

# GOG FACULTY DISCLOSURE INFORMATION

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** \*(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations.**

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

**All of the relevant financial relationships listed for these individuals have been mitigated.** However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

**NEW TERM** \*An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

NAME	Individual's Role(s) in Activity	Nothing To Disclose	DISCLOSURE <company & role>
<b>Speaker/Moderators</b>			
Bradley J. Monk, MD	Planning/Speaker		Honoraria: Consulting/Speaker: Agenus, Akeso, AstraZeneca, Aravive, Clovis, Eisai, Elevar, Genmab/Seattle Genetics, GOG Foundation, Inc. Gradalis, Iovance, Karyopharm, Merck, McKesson, Mersana, Myriad, Novocure, Pfizer, Roche/Genentech, Sorrento, Tesaro/GSK, VBL
Leslie Randall, MD	Planning/Speaker		Consulting fee: Agenus, Clovis, Myriad, Mersana, GSK/Tesaro Research Grant/ Contractor: Merck, Pfizer
Brian Slomovitz, MD	Speaker		Consultant: Abbvie, AstraZeneca, Clovis, GSK, Genentech, Merck, Myriad
Michelle Small	Staff	x	
Jill Reese	Staff	x	

# GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

## **Accreditation Statement**

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

## **AMA PRA Category 1 Credits™**

The GOG Foundation, Inc. designates this live activity for a maximum of **1.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Method of Participation**

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.



# AGENDA

- 6:00 pm – 6:07 pm**    **Welcome & Introduction**  
Bradley J. Monk, MD, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, Arizona, USA
- 6:07 pm – 6:20 pm**    **The Current Therapeutic Landscape in Cervical Cancer**  
Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA
- 6:20 pm – 6:35 pm**    **Emerging Therapies and Clinical Trials**  
Leslie Randall, MD, Dianne Harris Wright Professor and Director, Division of Gynecologic Oncology, Massey Cancer Center, Virginia Commonwealth University
- 6:35 pm – 6:50 pm**    **Targeted Approach Using ADC'S and The Mechanism of Action**  
Bradley J. Monk, MD, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, Arizona, USA
- 6:50 pm – 7:15 pm**    **Treatment, Toxicity and Research to Practice, an Expert Panel Discussion**  
All Session Faculty



# POLLING QUESTION 1

**What region of the world are you from?**

- a) U.S. – West Coast
- b) U.S. - Midwest
- c) U.S. – Southwest
- d) U.S. – East Coast
- e) Europe
- f) Asia
- g) Other

# POLLING QUESTION 2

**How many years have you been in practice?**

- a) 1 – 5 Years
- b) 6 – 10 Years
- c) 10 – 15 Years
- d) 15 – 25 Years
- e) 25+ Years

# POLLING QUESTION 3

**What is your specialty?**

- a) Fellow
- b) Attending
- c) Practicing
- d) Senior/Retired
- e) Industry
- f) Nurse/PA



# POLLING QUESTION 4

**Does your site participate in GOG Trials?**

- a) No
- b) Yes, Enroll > 3 trials
- c) Yes, Enroll < 3 trials

# POLLING QUESTION 5

**If TV is approved by the FDA, what is your preferred second line treatment for cervical cancer beyond immune checkpoint inhibitor?**

- a) Gemcitabine
- b) Topotecan
- c) Irinotecan
- d) Pemetrexed
- e) Tisotumab Vedotin

# POLLING QUESTION 6

**Assuming that Cemiplimab and Balstilimab get approval in second line, which one do you use in the PDL1 positive?**

- a) Cemiplimab
- b) Balstilimab
- c) Pembrolizumab